DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2019-N-5900]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Endorser Status and Explicitness of Payment in Direct-to-Consumer Promotion

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRAMain. Find this particular information collection by selecting “Currently under Review - Open for Public Comment” or by using the search function. The title of this information collection is “Endorser Status and Explicitness of Payment in Direct-to-Consumer Promotion.” Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Endorser Status and Explicitness of Payment in Direct-to-Consumer Promotion

OMB Control Number 0910--NEW

I. Background

Section 1701(a)(4) of the Public Health Service Act (42 U.S.C. 300u(a)(4)) authorizes FDA to conduct research relating to health information. Section 1003(d)(2)(C) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 393(d)(2)(C)) authorizes FDA to conduct research relating to drugs and other FDA regulated products in carrying out the provisions of the FD&C Act.

The Office of Prescription Drug Promotion’s (OPDP) mission is to protect the public health by helping to ensure that prescription drug promotion is truthful, balanced, and accurately communicated. OPDP’s research program provides scientific evidence to help ensure that our policies related to prescription drug promotion will have the greatest benefit to public health. Toward that end, we have consistently conducted research to evaluate the aspects of prescription drug promotion that are most central to our mission. Our research focuses in particular on three main topic areas: advertising features, including content and format; target populations; and research quality. Through the evaluation of advertising features, we assess how elements such as graphics, format, and disease and product characteristics impact the communication and understanding of prescription drug risks and benefits; focusing on target populations allows us to evaluate how understanding of prescription drug risks and benefits may vary as a function of audience, and our focus on research quality aims at maximizing the quality of our research data through analytical methodology development and investigation of sampling and response issues. This study will inform the first topic area, advertising features.
Because we recognize that the strength of data and the confidence in the robust nature of the findings is improved by utilizing the results of multiple converging studies, we continue to develop evidence to inform our thinking. We evaluate the results from our studies within the broader context of research and findings from other sources, and this larger body of knowledge collectively informs our policies as well as our research program. Our research is documented on our homepage, which can be found at: https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm090276.htm. The website includes links to the latest Federal Register notices and peer-reviewed publications produced by our office. The website maintains information on studies we have conducted, dating back to a survey on direct-to-consumer (DTC) advertisements conducted in 1999.

Advertisers have used celebrity endorsers for years, and DTC pharmaceutical promotion is no different. As researchers studied the influence of celebrity endorsers, they theorized that a correspondence bias occurs in which people believe that endorsers truly believe what they are saying. LaTour and Smith (Ref. 1) examined whether a pharmacist, physician, celebrity, or consumer would be most persuasive in advertisements for four different types of OTC products. They found that endorsements by expert physicians and pharmacists were the most likely to lead to purchase intentions, followed by endorsements by consumers, and lastly, by celebrities. The type of OTC product did not affect the persuasiveness of an endorsement.

Bhutada and Rollins (Ref. 2) recently completed a study examining the role of endorser type (i.e., celebrity vs. expert vs. non-celebrity), and endorser and consumer gender in product DTC ads. They found, like LaTour and Smith (Ref. 1), that expert endorsers were thought of as higher in credibility and generally resulted in the same amount of attention as celebrities. The authors did not find that endorsement by experts resulted in greater consumer intention to pursue the drug product.
We propose to extend previous research by examining four types of endorsers in two separate studies (celebrity, physician, patient, non-celebrity influencer\(^1\)) and examining whether the presence of a disclosure of their payment status influences participant reactions. We propose to also test two different types of disclosure language--one direct and more consumer-friendly, and one less direct.

To complete this research, we propose the following concurrent studies.\(^2\)

**Study 1**

<table>
<thead>
<tr>
<th>Payment Disclosure</th>
<th>Celebrity</th>
<th>Physician</th>
<th>Patient</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Present</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>150</td>
</tr>
<tr>
<td>Absent</td>
<td>33</td>
<td>33</td>
<td>33</td>
<td>99</td>
</tr>
<tr>
<td>Total</td>
<td>83</td>
<td>83</td>
<td>83</td>
<td>249</td>
</tr>
</tbody>
</table>

---

\(^1\) A “non-celebrity influencer” is a person who has gained a following on a blog, a Twitter feed, or other social media outlet. In the 60-day notice, the term “influencer” was used; we have added language to specify influencers who were not previously celebrities before their social media activities.

\(^2\) For case allocation, the literature suggests that some proportion of consumers may not recall seeing the disclosure statement in the advertisement (see, for example, Boerman et al; Ref. 3). Rather than allotting equal numbers of cases to each condition, we will assign more cases to the disclosure present condition to increase power in these cells.
Study 1 will manipulate endorser type (three levels: celebrity, physician, patient) and payment disclosure (two levels: present, absent) within a print DTC ad for a fictitious acne product. For this study, we will recruit 654 general population individuals (249 pretest; 405 main study) from the Kantar Lightspeed national nonprobability internet panel. All participants must report familiarity with the celebrity to be included in our study. The celebrity will be one who has publicly spoken out about acne. We are not divulging the identity of the celebrity in this public forum to maintain the integrity of our research process. Stock photos will be used to depict a physician and a patient in the other experimental conditions. Participants will be randomly assigned to see one of the endorsers and to see the ad either with or without a payment disclosure. The payment disclosure in Study 1 will be determined in cognitive testing but will be similar to: “[Endorser] has been paid to appear in this ad for Drug X.”

Study 2

Table 2a.--Study 2 Design--Pretest
(0.80 power, 0.10 alpha, small effect size f=.2)

<table>
<thead>
<tr>
<th>Payment Disclosure</th>
<th>Endorser</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Influencer</td>
<td>Patient</td>
</tr>
<tr>
<td>Present-Direct</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Present-Indirect</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Absent</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td>Total</td>
<td>133</td>
<td>133</td>
</tr>
</tbody>
</table>

Table 2b.--Study 2 Design--Main Study
(0.90 power, 0.05 alpha, small effect size f=.2)

<table>
<thead>
<tr>
<th>Payment Disclosure</th>
<th>Endorser</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Influencer</td>
<td>Patient</td>
</tr>
<tr>
<td>Present-Direct</td>
<td>81</td>
<td>81</td>
</tr>
<tr>
<td>Present-Indirect</td>
<td>81</td>
<td>81</td>
</tr>
<tr>
<td>Absent</td>
<td>54</td>
<td>54</td>
</tr>
<tr>
<td>Total</td>
<td>216</td>
<td>216</td>
</tr>
</tbody>
</table>
In Study 2, we will also manipulate endorser type, examining a patient and an internet influencer, one who provides online content to a number of followers. We will also manipulate the explicitness of the payment disclosure, resulting in a 2 (endorser: influencer, patient) by 3 (payment disclosure: present-direct, present-indirect, absent) between-subjects design. The disclosure will be direct (e.g., “Paid ad...”), indirect (e.g., #sp for “sponsored”), or absent. The setting for this study will be an Instagram post for a fictitious endometriosis product. This study partially replicates Study 1 and extends it by further examining the explicitness of payment as another manipulated variable and using a different set of endorser types and in a different promotional setting.

For Study 2, we will recruit 698 (266 pretest; 432 main study) followers of an internet influencer who maintains an Instagram page with more than 500,000 followers and has posted about endometriosis. As in the first study, we are not revealing the influencer’s identity in this public forum to maintain the integrity of the study.

In both studies, we are interested in the role of endorsement and disclosure of payment status on participants’ recall, benefit and risk perceptions, and behavioral intentions. Participants will view one promotional piece and answer questions via the internet. The study is expected to take less than 20 minutes to complete. Dependent variables will include attention to disclosure statement and risk/benefit information; retention of risk/benefit information; recognition of piece as promotion and endorser as paid; perceived benefits and risks, attitudes toward the product, endorser, and ad; and behavioral intentions, such as asking a doctor about the drug.

In the Federal Register of January 28, 2020 (85 FR 4994), FDA published a 60-day notice requesting public comment on the proposed collection of information. FDA received six submissions that were PRA-related. One submission (https://www.regulations.gov/docketBrowser?rpp=25&po=0&dct=PS&D=FDA-2019-N-5900&refD=FDA-2019-N-5900-0001) was a brief statement of support for the research and is not addressed further. Within the remaining five submissions, FDA received multiple comments
that the Agency has addressed below. For brevity, some public comments are paraphrased and, therefore, may not reflect the exact language used by the commenter. We assure commenters that the entirety of their comments was considered even if not fully captured by our paraphrasing in this document. The following acronyms are used here: DTC = direct-to-consumer; FDA and “The Agency” = Food and Drug Administration; OPDP = FDA’s Office of Prescription Drug Promotion; and FTC = Federal Trade Commission.

(Comment 1) One comment suggested that the proposed research, at least in part, is duplicative of information otherwise reasonably available to FDA. The comment pointed out that the Notice cites three scientific references, and it does not address the other literature that exists on the subject of endorsers in advertising. The comment recommended that FDA assemble and review the relevant literature on endorsement to ensure the research questions have not already been answered.

(Response) A literature review was conducted as part of this project that identified relevant literature. We identified a significant gap in the literature regarding the impact of social media influencers in prescription drug DTC advertisements, as well as a lack of information about the impact of explicit payment disclosure. The research questions outlined in our proposed research were designed to address this gap.

(Comment 2) One comment suggested that, although the studies contain clear variables, they appear to lack clearly defined primary outcomes and prespecified hypotheses for testing. The comment also noted that the studies do not appear to be designed to account for Type I error; thus, the results may be uninterpretable. The comment recommended that FDA propose a primary endpoint for each study and power each study to test it.

(Response) Specific hypotheses have been developed for each of the outcome variables, as described earlier in the notice. We will adjust for multiple comparisons using the Bonferroni correction.
(Comment 3) One comment suggested that it is unclear how FDA came up with the proposed sample sizes for the two related studies. For example, the comment stated that the chart for pretest 1 contains the following notation: "(0.80 power, 0.10 alpha, small effect size f=.2)," but it is unclear what f=.2 means in this context. The comment requested that FDA explain what statistical model it used to estimate the study size and how it determined that the relevant effect size is .2.

(Response) f = .2 is a common standard used to calculate small effect size in experimental studies (Ref. 4). We used G*Power to estimate study size (Ref. 5).

(Comment 4) One comment suggested that the proposed research is unnecessary to the proper performance of FDA’s functions because the FTC takes the lead on regulating endorsement. The comment stated that FDA has not addressed the extensive framework and guidance available from the FTC on this topic. The comment further stated that, although use of an endorser might conceivably inform an assessment of whether advertising or promotion is false or misleading, it is not clear how FDA views this new research on endorser status as fitting into its core regulatory jurisdiction or activities.

(Response) FDA and the FTC have a long history of working collaboratively to protect American consumers. While the FTC does regulate endorsement in many types of commercial advertisements, FDA has authority to regulate prescription drug advertising with respect to the safety and effectiveness of such drugs. In line with FDA’s responsibility to ensure that prescription drug advertising and other promotional communications are truthful and non-misleading, the present research will provide data on how elements related to endorsement presentations in prescription drug promotion impact audience perception and comprehension. Collecting this data is critical to FDA’s science-based approach to assessing prescription drug promotion to determine whether it communicates information about prescription drugs to consumers in a truthful, non-misleading way. We note that as part of the process of developing the present research, FDA carefully evaluated the FTC guidance on endorser issues.
(Comment 5) One comment recommended that alignment and input should be obtained from the FTC regarding the design of the study and usability of the results.

(Response) We evaluated the current FTC guidance on endorsement disclosure when developing this study and all relevant elements of its design, including our hypotheses, test stimuli, etc.

(Comment 6) One comment suggested that the research may be skewed by the influence of a particular celebrity. The comment recommended that the study be amended so it is not subject to bias by the influence of one particular well-known celebrity.

(Response) Familiarity with an endorser has shown to be an important factor in attention to DTC advertisements, but the evidence is less strong that familiarity uniquely affects other outcomes such as behavioral intention (see, for example, Refs. 2 and 6). The celebrity used in Study 1 will have high levels of public recognition, so we anticipate few participants will be filtered out due to low levels of familiarity with endorser. We recognize that the individual characteristics of the celebrity may drive responses. This possibility is an unavoidable limitation of the study design, and we will be transparent when reporting results.

(Comment 7) One comment recommended that FDA use #ad instead of #sp. The comment noted that FTC has stated that #ad is an effective disclosure of sponsorship.

(Response) Our review of current practices shows that vendors continue to indicate endorsement by #sp online. An indirect disclosure such as #sp serves as a useful comparator to a direct disclosure such as “Paid ad…”, helping us answer the research question of whether direct and indirect acknowledgements of endorsement vary in their influence on attitudes and perceptions.

(Comment 8) One comment recommended that FDA incorporate some type of control into each study.
Response) We have designed these studies to include a control. The control, in both studies, is a duplicate version of the promotion featuring endorsement by a patient, as opposed to a celebrity or influencer, without inclusion of a payment disclosure.

(Comment 9) One comment suggested that FDA should ensure that the hypothetical products used in the proposed surveys do not too closely resemble real products. For example, the conditions of use and the risk of the hypothetical products should not mirror FDA-approved labeling language for any marketed products. In addition, FDA should only present hypothetical drug advertisements for diseases with many treatment options from multiple sponsors. Otherwise, the comment states that FDA’s research could inadvertently harm one particular sponsor.

(Response) The prescription drugs used in this study, while based on existing prescription treatments, are fictitious with names and branding that do not mirror any marketed products. Although we have created the pieces to be as realistic as possible, FDA does not intend to single out any real product on the basis of our fictional promotion. We specifically use fictitious products and materials to avoid the confound of prior knowledge of actual products. Moreover, it is the endorser type and messaging around the endorsement disclosure that are being investigated. The fictional drug is not a study variable and therefore is held constant.

(Comment 10) One comment suggested that the route of drug administration may influence the participants’ responses, as oral administration and inhaled medication is preferable compared to injections. Therefore, the comment suggested that the study use fictitious drugs with routes of administration that are similar to top advertised DTC prescription drugs.

(Response) This is outside the scope of study objectives. The goal of the studies is to understand the effect of endorsement and payment disclosure on perceived risks and benefits of DTC promotion. Because the same drug is being presented in each experimental condition, the effects of mode of administration are being held constant in each study; therefore, any observed effects are not related to the route of administration chosen.
(Comment 11) One comment suggested that in order to increase internal validity, the location of the disclosures in the promotional pieces should be consistent across endorser and/or disclosure type.

(Response) FDA will ensure that for each study, disclosures will appear in the same area of the promotional piece, using similar font and style treatment.

(Comment 12) One comment suggested that acne and endometriosis drugs are not representative of the top advertised prescription drugs and that the current proposed study design, therefore, may not represent the most advertised DTC drugs in the market.

(Response) The purpose of the studies is to understand the effect of endorsement and payment disclosure on perceived risks and benefits of DTC promotion. The value of our approach is random assignment to experimental conditions and control of extraneous variables. Choice of drug is not a study variable and therefore held constant. Although the type of drug may play a role in the perceptions of risks and benefits, the value of our study is the comparisons between experimental conditions.

(Comment 13) Two comments suggested that participants’ unfamiliarity with the proposed conditions may bias their responses, so it may be more useful to include only patients with the condition as participants in each study.

(Response) The study population is those who are exposed to prescription drug advertisements. For Study 1, we chose a high incidence condition (acne) so that it would be relatable to a large segment of the population. Regardless of whether or not the condition is personally salient, the public is still exposed to these advertisements.

For Study 2, we chose a condition that is important to the influencer in the study--and this information would be known to many of her followers, who are the research audience for Study 2. Engagement and e-Word of Mouth have been shown to be important behavioral outcomes from social media promotion (Ref. 3). Thus, in a real-world setting, audience members may
choose to comment on or share the advertised content with family or friends, regardless of whether or not they have the health condition themselves.

For both studies, we ask about personal experience and involvement with the health condition, and we will assess whether these variables have any effects.

(Comment 14) One comment suggested ensuring that neutral language is used when recruiting for Study 1’s general population, so as not to select for participants that are more susceptible to the celebrity’s influence. For example, the comment suggested that the study ask participants if they “recognize” the celebrity vs. if they are a “fan” of the celebrity.

(Response) In screeners for both studies, we ask if participants are “familiar” with celebrities/influencers, thus maintaining neutral language.

(Comment 15) Two comments suggested participants’ familiarity with the endorser may bias responses and limit participant demographics. One comment suggested that recruiting participants from the follower list of an Instagram influencer, as proposed in Study 2, may skew the average age of the participants to be younger, especially if the influencer chosen for this study is a “handheld name” versus a “household name.” The comment also suggested that the participants may have a female skew. Another comment suggested that the current inclusion criteria should be expanded to also include followers of influencers with similar content, recognition, and follower demographics as the endorser being tested, which will increase external validity by encompassing viewers that would likely see the post through suggestions via Instagram’s algorithm.

(Response) Familiarity with an endorser has been shown to be an important factor in attention given to DTC advertisements (Ref. 2), and that is one driver of an influencer’s value as an endorser. By including endorser type as an experimental condition, we seek to isolate these effects. Thus, the biases inherent in these relationships are a necessary aspect of this topic area.

The study design is a between-subjects design. Because participants are only exposed to one promotional piece, the specific effects from behavioral bias can be isolated.
We agree with the commenter that Study 2 will have a younger, female skew. This is consistent with Instagram’s audience more generally (Ref. 7). Advertisers who use Instagram influencers as endorsers will access the same audience (i.e., Instagram followers) as in our study. To minimize confounds, we will limit the sample to the influencer’s followers, who are likely to be the most influenced by her. Future research can be conducted on whether our findings extrapolate to men and older audiences.

(Comment 16) One comment suggested that to account for the potential bias in these studies, it would be useful to include questions relating to participant demographics in the surveys, such as age, gender, and attitude toward the celebrity or influencer, if they are not already included.

(Response) The survey includes questions about participant demographics and attitude toward endorser.

(Comment 17) One comment suggested that in order to prevent bias, the study should exclude consumers who work in healthcare or marketing settings, primary care providers that spend less than 50 percent of their time on patient care, and Department of Health and Human Service employees.

(Response) The studies in this research do not include physician participants. Consumers will be excluded if they work for a pharmaceutical company, an advertising agency, a market research firm, or the U.S. Department of Health and Human Services. They will also be screened out if they are not familiar with the celebrity/influencer, and, for Study 2, if they are biologically male, as men cannot have endometriosis.

(Comment 18) One comment suggested that the questionnaire is too long and recommended deleting questions or rewording.

(Response) We have had individuals unfamiliar with the study test the survey for length, and we found it takes less than 20 minutes to complete. Moreover, we will also conduct
pretesting to check timing and make adjustments, if necessary, based on the data from those pretests.

(Comment 19) One comment suggested we should consistently use balanced Likert scales with a neutral midpoint.

(Response) This is a matter of debate in the literature and has never been resolved. Many of our measures derive from previously validated scales, and we prefer to maintain the scales on which they were validated. However, where appropriate, we do use 5-point Likert scales with a neutral midpoint.

(Comment 20) One comment recommended rewording Q17 (in both study questionnaires) to state “What do you remember about the safety information presented?”

(Response) Q17 is a validated (OMB control number 0910-0861) closed-ended item asking how much risk information was read (with a thumbnail image highlighting the important safety information). In order to increase quality of response, we will keep the closed-ended item. Moreover, open-ended questions take longer to answer, and we want to maintain an appropriate length of time to complete the survey.

(Comment 21) One comment suggested that the adjectives that the respondent is asked to rank in Q18a-Q18e (Study 1) are redundant with only nuanced differences that may not be distinguishable to respondents, and therefore suggested these items be deleted. If they are retained, the comment suggested labeling answer choice #3 with “Neither unimportant nor important.”

(Response) These items were adapted from Zaichowsky’s Disease State Involvement scale (Ref. 8). The original validated items used a 7-point scale without a labeled midpoint. To be consistent with most of the items and with previous comments, we reduced the scale to 5 points. However, we did not include a labeled midpoint because it could result in under-response for values 2 and 4. This response applies to Q20 (Study 2) as well, where we want to ensure that individuals taking Study 2 on their mobile devices are not overwhelmed.
One comment suggested that Q20 and Q21 (Study 1) may be redundant, and since Q20 uses more consumer-friendly language to seek respondent opinion on effectiveness of drug, the comment recommended removing Q21. This comment also applies to Q22 and Q23 of Study 2.

(Response) We will remove Q21 (Study 1) and Q23 (Study 2).

One comment recommended that Q22 (Study 1) be framed differently to help understand how endorsers influence the understanding of safety and risk and that the answer choice should have an option for respondents who do not know.

(Response) We decline to make the recommended change because this is a validated item that FDA has used in past survey experiments to measure perceived risk likelihood.

One comment questioned the utility of asking whether an endorser is “Attractive,” “Classy,” and “Elegant” (Q30, Study 1); whether a drug name and endorser name “go together” (Q31, Study 1); and how a subject feels about the life and values of the endorser (Q32, Study 1). The comment recommended that FDA consider deleting these questions.

(Response) In the marketing literature on celebrity endorsements, these three elements are well established as important moderators in attitude toward advertisement and behavioral intention. “Attractive,” “Classy,” and “Elegant” are elements in a 15-item scale validated by Ohanian (1990) to measure endorser credibility (Ref. 9). The literature refers to “whether a drug name and endorser go together” as “product match-up” (Ref. 10), and high match-up was recently shown to be predictive of behavioral intention for e-cigarettes (Ref. 11). The level of identification that consumers have with a celebrity endorser has been shown to influence how consumers attend to and process information in an advertisement (Refs. 12 and 13). Thus, we will maintain these questions.

One comment suggested that, if the research is intended to assess the influence of endorsers or their payment status, Q15-Q17 in both surveys and Q20-Q27 for Study 1 and Q22-Q29 for Study 2 appear to be outside of the scope. With these questions, subjects
would be asked to assess the risks and benefits of a drug based on an advertisement. The comment recommended that FDA delete these questions or revise them so they are focused instead on payment or endorsement.

(Response) As part of the examination of the effect of the endorser, one purpose of the study is to understand the effect of endorsement and payment disclosure in DTC promotion on perceived risks and benefits of a prescription drug. The questions mentioned in this comment measure these dependent variables—consumer perceptions of risk and benefit information presented in the promotion. We will maintain these questions in order to assess if endorsement and the payment disclosure have any effects on perceptions of risk and benefit information.

(Comment 26) One comment suggested that the structure of Q28 (Study 1) and Q30 (Study 2) should be consistent with other questions in this survey. It recommended changing each question to include “What is the likelihood” (e.g., What is the likelihood that you would ask your doctor to prescribe) and presenting answer choices in a 5-point Likert scale.

(Response) We will assess how this item functions in pretesting and make any change that is warranted.

(Comment 27) One comment suggested moving Q28a (Study 1) and Q30a (Study 2) up in the survey, after Q13, as this question could function as a priming question after initial viewing of ad.

(Response) Because this item is part of a validated scale (Ref. 14), we will maintain it at its current location in both surveys.

(Comment 28) One comment suggested that Q31 (Study 1) and Q33 (Study 2) construct and answer choices should align with other similarly constructed question and answer choices in this section of the survey.

(Response) This is a validated item (Ref. 15) to measure endorser-product match-up. Therefore, we will maintain the current format.
(Comment 29) One comment suggested that Q33 (Study 1) and Q35 (Study 2) could cause respondent confusion regarding what is meant by “background,” which could lead to uninterpretable results. It recommended explicitly stating what is meant by “background” (e.g., “I prefer a product recommended by an endorser because of his/her experience with this illness”).

(Response) This is a validated item (Ref. 16) that measures identification with endorser; thus, we will maintain its original form in both studies.

(Comment 30) One comment mentioned that Q43-Q45 (Study 1) and Q45-Q47 (Study 2) probe the level of influence that endorsers have over respondents and suggested adding a question asking if the respondent has followed the advice of an endorser.

(Response) Q36-Q48 (Study 1) and Q45-47 (Study 2) are validated items in the celebrity-persona parasocial-involvement scale (Ref. 17); thus, we will maintain the integrity of the scale and not add another question in this series.

(Comment 31) One comment suggested that the debriefing statements in both questionnaires may serve the respondent better if placed earlier in the document as a disclaimer and suggested placing the disclaimer language prior to showing the promotional piece.

(Response) To maximize the attention participants give to this survey task, we do not wish to inform them of the information in the debriefing statement until they have completed the survey.

(Comment 32) One comment suggested that Q18 and Q19 (Study 2) are redundant, although respondents may not define a paid endorser post as advertising, and that the items seem irrelevant. It recommended removing Q18 from the questionnaire.

(Response) Previous experimental studies on social media promotion have found that participants did not consistently notice a payment disclosure or interpret a sponsored post as advertising (Ref. 1). These issues are central to the question of whether consumers process
payment disclosures. Moreover, participants in cognitive testing distinguished between the two items.

(Comment 33) One comment noticed that Q20 in Study 2 is similar to Q18 in Study 1; however, answer choices are not provided in a similar construct. The comment recommended utilizing a 5-point Likert scale to measure the outcome.

(Response) We simplified the response scale for Study 2 items, where possible, to account for anticipated higher usage of mobile devices. Because we prefer a larger number of response options in general, we plan to maintain the 5-point Likert scale for Study 1, but use the 3-point scale in Study 2 to account for mobile devices.

(Comment 34) One comment suggested that Q24 (Study 2) could be framed differently to help understand how endorsers influence the understanding of safety and risk. The comment recommended asking “Do you recall the risk associated with the medication?” and suggested that the answer choice should have an option for respondents who do not know.

(Response) Q24 and Q25 from Study 2 are closed-ended questions that ask about recall of drug benefits and risks. To be balanced, the question stem and response options should be parallel between the two items. Moreover, we cannot add additional open-ended questions to the survey without increasing participant fatigue. Thus, we will maintain the closed-ended nature of the question. We recognize that this will be a difficult question for participants, and therefore, we prefer not to provide an option for “don’t know.”

FDA estimates the burden of this collection of information as follows:

<table>
<thead>
<tr>
<th>Activity</th>
<th>No. of Respondents</th>
<th>No. of Responses per Respondent</th>
<th>Total Annual Responses</th>
<th>Average Burden per Response</th>
<th>Total Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1 Screener</td>
<td>933</td>
<td>1</td>
<td>933</td>
<td>0.08 (5 minutes)</td>
<td>74.64</td>
</tr>
<tr>
<td>Study 1 Pretest</td>
<td>249</td>
<td>1</td>
<td>249</td>
<td>0.33 (20 minutes)</td>
<td>82.17</td>
</tr>
<tr>
<td>Study 1 Main Test</td>
<td>405</td>
<td>1</td>
<td>405</td>
<td>0.33 (20 minutes)</td>
<td>133.65</td>
</tr>
<tr>
<td>Study 2 Screener</td>
<td>1,417</td>
<td>1</td>
<td>1,417</td>
<td>0.08 (5 minutes)</td>
<td>113.36</td>
</tr>
<tr>
<td>Study 2 Pretest</td>
<td>266</td>
<td>1</td>
<td>266</td>
<td>0.33 (20 minutes)</td>
<td>87.78</td>
</tr>
</tbody>
</table>
II. References

The following references are on display with the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, and are available for viewing by interested persons between 9 a.m. and 4 p.m., Monday through Friday; these are not available electronically at https://www.regulations.gov as these references are copyright protected. Some may be available at the website address, if listed. FDA has verified the website addresses, as of the date this document publishes in the Federal Register, but websites are subject to change over time.


Dated: December 1, 2020.

Lauren K. Roth,

*Acting Principal Associate Commissioner for Policy.*

[FR Doc. 2020-26799 Filed: 12/4/2020 8:45 am; Publication Date: 12/7/2020]